Samsara BioCapital — Full Portfolio

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)inAGAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)OLOlivier Litzka(Director)in

Board seatSrinivas Akkaraju· per SEC Form D

Co-investorsANAndera PartnersSRSR One Capital ManagementYSYsios CapitalADAdams Street PartnersBOBoulder VenturesCACatalys Pacific+1 more

Neurogene develops gene therapy treatments for rare neurological diseases.

BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US

RMRachel McMinn(Founder and Chief Executive Officer)inRMRachel McMinn, Ph.D.(Founder and Chief Executive Officer)

BoardCory Freedland(Director)inStephen Biggar(Director)

Board seatRBRobert Baffi· per SEC Form D

Co-investorsECEcoR1 CapitalCACasdin CapitalREREDMILERTRTW Investments L.P.WIWilliam Blair

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

PHPaul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPJPaul J. Hastings(Chief Executive Officer)in

BoardJCJill Carroll(Director)in

Board seatMichael Dybbs· per SEC Form D

Co-investorsNENew Enterprise Associates (NEA)RARA CapitalSRSR One Capital ManagementAMAmgen VenturesLOLogosNONorwest Venture Partners+1 more

Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.

BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

William J. Newell(Executive Officer, Director)JCJane Chung(Chief Executive Officer)inHGHans-Peter Gerber(Chief Scientific Officer)inDPDavid Pauling(Chief Administrative Officer and General Counsel)inJFJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in

Board seatMichael Bryan Dybbs· per SEC Form D

Co-investorsOWOwl CapitalSOSolasta VenturesSVSV Health InvestorsVIVida Ventures

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.

BiotechDigital HealthMedical DevicesHigh Point, US

RHRudy Howard(Executive Officer)inSHStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)PSPaul Sekhri(Chairman, President, and Chief Executive Officer)inMTMichael Tung(Executive Vice President and Chief Financial Officer)in

Board seatSrinivas Akkaraju· per SEC Form D

Co-investorsJDJDRF T1D Fund

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)CBCraig B. Thompson, M.D.(Founder)BGBrian Goff(Chief Executive Officer)in

Co-investorsARARCH Venture PartnersTHThird Rock VenturesFLFlagship Ventures

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

MBMartin Babler(President, Chief Executive Officer and Chairman of the Board)inMBMark Bradley(Chief Development Officer)inKBKolbot By(SVP, Head of Technical Operations)inJDJack Danilkowicz(Chief Commercial Officer)inJDJörn Drappa(Chief Medical Officer)inDMDavid M Goldstein(Chief Scientific Officer)in

Co-investorsFOForesite CapitalNENextech InvestOROrbiMedSRSR One Capital ManagementVEvenBio PartnersWEWestlake Village BioPartners+1 more

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

DEDr. Edgar G. Engleman(Founder)

Co-investorsPFPfizer Venture InvestmentsRARA CapitalSOSofinnova VenturesVIVivo CapitalNANan Fung Life SciencesNONovo Holdings+3 more

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.

BiotechHealthtech

CSCarmine Stengone(President and Chief Executive Officer)inCNCarmine N. Stengone(President, Chief Executive Officer and Director)inPTPeter T. Slover(Chief Financial Officer)inDSDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in

Co-investorsHAHadean VenturesRERed Tree VentureCACasdin CapitalFRFranklin TempletonJJJJDCSESectoral Asset Management+1 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)OMOmega Funds

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechHealthtechBerkeley Heights, US

Srinivas Akkaraju(Director & Co-founder)MDMike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)

Co-investorsINInvusRTRTW Investments L.P.

Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

BiotechSouth San Francisco, US

Josh Lehrer(Executive Officer, Director)KSKatherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in

Co-investorsVEVersant Ventures

Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.

BiotechDigital HealthHealthtechMedical DevicesWayne, US

Wesley H. Kaupinen(President, Chief Executive Officer and Director)Matthew E. Korenberg(Chief Financial Officer, Treasurer and Secretary)inKathleen Goin(Chief Operating Officer)inJeffrey Martini(Chief Scientific Officer)inAKAshley Kline(Chief Commercial Officer)in

Co-investorsBIBioAdvanceFRFrazier Life SciencesAGAgent Capital

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.

BiotechDeep TechHealthtechMedical Devices

AAAndrew Anzalone(Co-founder and Head of Platform)inDLDavid Liu(Co-founder)inARAllan Reine(Chief Executive Officer)inMAMohammed Asmal(Chief Medical Officer)inALAnn Lee(Chief Technical Officer)inSMSvetlana Makhni(Chief Financial Officer)in

Co-investorsARARCH Venture PartnersGVGV (Google Ventures)NENewpath PartnersF-F-Prime CapitalOUOUP (Osage University Partners)ARArrive

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Co-investorsARARCH VentureARARCH Venture PartnersECEcoR1 CapitalPOPolaris Partners

SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.

BiotechHealthtechMedical DevicesAliso Viejo, US

GSGlenn Sussman(Co-founder)inMYMalik Y. Kahook(Co-founder)inPMPatrick Mooney(CEO)

BoardJake Merrill(Director)GPGeoff Pardo(Director)BKBilal Khan(Director)

Co-investorsNENew Enterprise Associates (NEA)RARA CapitalSASands Capital VenturesVEVensana Capital

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)inAAAllison Ambrose(General Counsel)inADAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)AHAdam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsOROrbiMedACAccess IndustriesACAccess BiotechnologyBABain Capital Life SciencesDEDecheng CapitalTCTCG Crossover+2 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Board seatMichael Dybbs· per SEC Form D

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)RARA CapitalSASanofi VenturesMAMass General Brigham VenturesREREDMILE+9 more

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)inSMSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

BoardJLJay Lichter(Director)inTRTighe Reardon(Executive Officer)

Board seatMMMarcos Milla· per SEC Form D

Co-investorsFRFrazier Life SciencesLILightspeed Venture PartnersAVAvalon BioVenturesPAPappas CapitalPFPfizer Venture InvestmentsJ.J.P. Morgan Asset Management+1 more

OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.

BiotechDeep TechMedical DevicesMenlo Park, US

MSMani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers

BoardMYMatthew Young(Director)in

Board seatSrinivas Akkaraju· per SEC Form D

Co-investorsASAscenta CapitalLOLongitude CapitalF-F-Prime Capital

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.

BiotechHealthtechMedical DevicesChanhassen, US

Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)

BoardKlaus Veitinger(Director)inIEImran Eba(Executive Officer)in

Co-investorsOROrbiMedHEHealthQuest CapitalSVSV Health InvestorsACAction Potential Venture Capital Ltd.

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)AHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inANAmeet Nathwani, M.D.(Executive Officer, Director)in

Co-investorsARARCH Venture PartnersECEcoR1 Capital6 6 Dimensions CapitalGEGeneral CatalystINInnovation EndeavorsLELeaps by Bayer+5 more

Link Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors.

BiotechHealthtech

RMRobbie MajznerCMCrystal MackallJCJerry Cacia(Chief Operating Officer)inMWMark Wallet(Chief Scientific Officer)in

Co-investorsWIWing

Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics.

BiotechDeep TechHealthtechMedical DevicesSeattle, US

BFBrian Finrow(Founder)in

Co-investorsWEWestRiver Group

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

RHRachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)MKMitchell Keegan(Chief Development Officer)inWLWilliam LaRochelle(Chief Scientific Officer)inSMStacy M. Plum(Chief Technology Officer)

Co-investorsSASanofi VenturesTATaiho Ventures, LLCPFPfizer VenturesCACanaan PartnersCOConnecticut InnovationsPFPfizer Venture Investments+4 more

PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.

AI & Machine LearningBiotechDeep Tech

Co-investorsLILightstone Ventures

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)SMSusan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsTHThe Column GroupBABain Capital Life SciencesCACanaan PartnersRARA CapitalTCTCG CrossoverDEDeerfield Management Company+2 more

Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.

BiotechDeep TechHealthtechMedical Devices

BoardSASrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)

Co-investorsVEVersant VenturesGIGilead Sciences

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsPFPfizer VenturesRARA CapitalSVSV Health InvestorsPFPfizer Venture InvestmentsM M Ventures

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechHealthtechAgoura Hills, US

CAC. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardDavid Goeddel(Director)in

Board seatSASrini Akkaraju· per SEC Form D

Co-investorsNENextech InvestVIVida VenturesTHThe Column Group

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

VVVictor Velculescu(Founder and Board Director)inPBPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSTSusan Tousi(Chief Executive Officer)in

Board seatMichael Dybbs· per SEC Form D

Co-investorsAVAV8 VenturesFOForesite CapitalILIllumina VenturesINInitiate Venture PartnersMEMenlo VenturesOPOpen Field Capital+5 more

BiotechSouth San Francisco, US

MBMARTIN BABLER(Executive Officer, Director)in

BoardPTPETER THOMPSON(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Board seatSrinivas AkkarajuMichael Dybbs· per SEC Form D · $50M raise · filed Sep 2018

Co-investorsACAccess BiotechnologyMIMission BiocapitalSOSofinnova VenturesMIMission Bay CapitalNENew Leaf Venture PartnersOROrbiMed+1 more

A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.

BiotechDeep TechDigital HealthHealthtechMedical Devices

JRJim Robinson(CEO)in

Co-investorsTHThe Column Group

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical DevicesParis, FR

MDMarc de Garidel(CEO)in

Co-investorsANAndera PartnersCLClaret Capital PartnersMEMedicxiSOSofinnova PartnersTRTruffle CapitalMOMorgan Stanley

AI & Machine LearningBiotechDigital HealthHealthtech

Co-investorsDEDecheng CapitalVEvenBio PartnersACAccess IndustriesKLKleiner PerkinsWEWestlake Village BioPartners

Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).

BiotechDeep TechHealthtechFremont, US

YLYuling Luo(Co-founder, CEO and Chair)inSCSteve Chen(Co-founder, COO and Director)inYYYiyuan Yin(Co-founder, VP of Technology)inTWTod White(President)inJMJustin McAnear(CFO)inXMXiao-Jun Ma(CTO)

Co-investorsILIllumina VenturesQIQiming Venture Partners

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardFCFarah Champsi(Director)inJMJohn McKearn(Director)inPeter Moldt(Director)

Co-investorsALAlta PartnersNENew Enterprise Associates (NEA)RIRiverVest Venture PartnersRORoche Venture Fund

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(MD)KLKuo-Shyan Lin(PhD)DPDavid Perrin(PhD)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalGEGeneral CatalystLILightspeed Venture PartnersLOLongitude Capital+9 more

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)RERami Elghandour(Executive Officer, Director)in

BoardJCJill Carroll(Director)inABAli Behbahani(Director)inDYDerek Yoon(Director)inTATiba Aynechi(Director)in

Co-investorsLGLG Technology VenturesNENew Enterprise Associates (NEA)QUQuan CapitalSISixty Degree CapitalSOSolasta VenturesSRSR One Capital Management+5 more

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

JWJonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)MTMark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)RKRahul Kakkar(Director)inGreg Bell(Executive Officer)

Co-investorsALAlpha Wave GlobalBIBioBritVEvenBio PartnersJAJanus Henderson InvestorsREREDMILEVEvenBio Global Strategic+1 more

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

KFKevin Finney(Chairman, President and CEO)inJBJohn Borkholder(Executive Officer)in

BoardKBKristina Burow(Director)inTCThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARARCH Venture PartnersCACanaan PartnersMOMonograph Capital PartnersPFPfizer Venture InvestmentsNENewpath Partners

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalOROrbiMedTCTCG CrossoverTHThird Rock VenturesVEvenBio PartnersVIVida Ventures

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

GCGina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNENextech InvestRERed Tree VentureALAlly Bridge GroupJAJanus Henderson InvestorsPEPerceptive Xontogeny VentureTHThird Rock Ventures

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical DevicesJersey City, US

CAClarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)SOSusan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCACatalio Capital Management, LPRARA CapitalSOSofinnova VenturesCACatalio Capital ManagementNONovo Holdings

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

PRPierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMDMarie De Vulder(Chief Legal Officer Co-founder)inGPGuy Peeters(Chief Financial Officer Co-founder)inJGJohn-Paul Gallivan(Head of Development Co-founder)inFKFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsLOLongwood FundSOSofinnova VenturesBABAM ElevateFIFinchley Healthcare VenturesFOForbionLULuma Group+1 more

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

CNChiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsPAPacific Channel3E3E Bioventures CapitalARARCH Venture PartnersECEcoR1 CapitalGEGeneral CatalystLELeaps by Bayer+2 more

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

DHDavid Hallal(CEO)inMPMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in

Co-investorsECEcoR1 CapitalMPMPM BioImpactSOSoftBank Vision Fund

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

ALAnn Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSBSamuel Bjork(Director)inACAlexandra Cantley(Director)inSMSeiji Miyahara(Director)in

Co-investorsAVAvego BioScience CapitalGVGV (Google Ventures)MIMission BiocapitalNONovartis Venture FundRORoche Venture FundTATaiho Ventures, LLC+4 more

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)ASAlan Saghatelian, PhD(Co-Founder)DLDavid LiuinASAlan Saghetelian

Co-investorsNENewpath PartnersCRCRV (Charles River Ventures)NENextech InvestRARaptor GroupBIBiotechnology Value FundCACasdin Capital+1 more

Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.

BiotechDeveloper Tools

Co-investorsCICivilization Ventures Management, LlcCOCota CapitalILIllumina Ventures

Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.

Digital HealthHardwareHealthtechMedical DevicesSan Diego, US

CGCary Gunn(Co-founder and Chief Technical Officer)in

Co-investorsBIBioBritBOBoutique Venture PartnersCLClaremont Creek VenturesFUFusionX VenturesIPIPD CapitalSESeed Healthcare+3 more

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.

BiotechFintech

Co-investorsCACatalys PacificFRFrazier Life SciencesLILightspeed Venture PartnersRARA CapitalFRFrazier Healthcare Partners

Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.

BiotechHealthtechMedical Devices

Co-investorsAIAisling CapitalBIBioBritRIRidgeback Capital

Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.

BiotechMedical Devices

Co-investorsEUEuropean Investment BankANAndera PartnersCLClaret Capital PartnersNENew Enterprise Associates (NEA)SOSofinnova PartnersBIBiotechnology Value Fund+1 more

IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.

BiotechMedical Devices

Dr. Dhingra

Co-investorsAVAvoro Capital AdvisorsEIEIR VenturesKUKurma PartnersRARA CapitalSUSunstone CapitalVIVivo Capital+2 more

IonPath develops MIBIscope, a spatial proteomics platform that uses multiplexed ion beam imaging to simultaneously measure dozens of protein targets in preserved tissue samples for translational research and discovery.

BiotechDeep TechMedical Devices

Co-investorsHEHemisphere Ventures LLCNONorwich VenturesVEVertical Venture Partners

Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases.

BiotechMedical DevicesLa Jolla, US

DCDavid Campbell, Ph.D.(Executive Officer, Director)inTRTighe Reardon(Executive Officer)

BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)PTPeter Thompson, M.D.(Director)inStefan Heller(Director)

Co-investorsAVAvalon BioVenturesOROrbiMed

HealthtechSkokie, US

Sara Cotter(Executive Officer, Director, Promoter)Michael Dybbs(Director)Sara Brownstein(Director)Terrence Kearney(Director)Daniel Welch(Director)Steven Ryder(Director)

Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.

BiotechHealthtechWoburn, US

CDCyril De Colle(Founder)inCDCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JOJAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in

BoardDADAVID ALLISON(Director)in

Co-investors5A5AM VenturesOROrbiMedVEvenBio PartnersVIVivo CapitalRTRTW Investments L.P.VEvenBio Global Strategic+1 more

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)H(Hong (Kelsey) Chen(Chief Financial Officer)

BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)

Co-investorsECEcoR1 CapitalLALAVLILilly Asia VenturesRARA CapitalTHThe Innovation SpaceLOLogos

Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsTHThe Column GroupSASanofi Ventures

Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.

BiotechHealthtechResearch Triangle Park, US

BSBT Slingsby(Co-Founder & Executive Chairman)in

Co-investorsABAbingworthCACatalys PacificOROrbiMedKBKB Investment

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.

BiotechHealthtechCarlsbad, US

JAJames Appleman(SVP, R&D and CSO, Cofounder)PRPaulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCMCharles McDermott(President & CEO, Director)

BoardTodd J Harris(Director)in

Co-investorsBIBioBritBIBioRock VenturesBIBioqube VenturesOBOberland CapitalPOPolaris Partners

BiotechFremont, US

AVAvanish Vellanki(Executive Officer)in

Co-investorsBIBiotechnology Value FundJAJanus Henderson Investors

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

KSKen Song(Executive Officer, Director)inBHBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

BoardARAaron Royston(Director)in

Co-investorsSCScion Life SciencesSOSofinnova VenturesTCTCG CrossoverVEvenBio PartnersVEVersant VenturesVIVivo Capital+1 more

Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension.

BiotechDigital HealthHealthtechMedical Devices

JKJohn Kollins(Chief Executive Officer)in

Co-investorsCOCottonwood Technology FundZEZentynel Frontier Investments

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)RXRan Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)SSSamira Shaikhly(Executive Officer)in

Co-investorsCACatalio Capital Management, LPRARA CapitalVEVertex Ventures HCTHThird Rock Ventures

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

ARAaron Ring(Executive Officer, Director)inBMBeatrice McQueen(Chief Operating Officer)inSRSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)HUHirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsCOConnecticut InnovationsPFPfizer Venture InvestmentsSRSR One Capital ManagementAXAxial VCBIBiotechnology Value FundRORock Springs Capital